BRAF and colorectal carcinoma: They hypothesised that this could be a mechanism for IKKα driven therapy resistance [139] and found that inhibition of IKKα (theorised to also inhibit p45-IKK) or BRAF significantly increased the effects of 5-FU and irinotecan in patient derived CRC tumoroids.